Signatera Oncology Test Drives Natera’s (NTRA) Growth

1 week ago 9

Soumya Eswaran

Wed, March 4, 2026 astatine 6:10 AM CST 3 min read

Carillon Tower Advisers, an concern absorption company, released its fourth-quarter 2025 capitalist missive for the “Carillon Eagle Mid Cap Growth Fund”. A transcript of the missive tin beryllium downloaded here. The 4th fourth of 2025 saw mixed results for midcap stocks. Among the benignant indexes, the Russell Midcap® Growth Index decreased by 3.70%, portion the Russell Midcap® Value Index roseate by 1.41%. In the maturation index, materials achieved the highest implicit instrumentality astatine 17.51%. However, owed to their smaller value successful the index, their publication to wide returns was limited. The healthcare (up 1.13%) and existent property (up 0.24%) sectors were the lone different affirmative contributing sectors. Midcap stocks generated affirmative returns successful 2025 but trailed their 2024 yearly returns. The Russell Midcap Growth Index roseate by 8.66%, trailing the Russell Midcap Value Index’s 11.04% return. In the maturation index, utilities recorded the highest implicit instrumentality among each sectors, up 29.40%. The steadfast anticipates a favorable twelvemonth up for equity markets. The missive outlined imaginable opportunities successful Cyclicals, Healthcare, Information Technology, Financials, and Consumer Spending sectors done 2026. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Carillon Eagle Mid Cap Growth Fund highlighted Natera, Inc. (NASDAQ:NTRA) arsenic 1 of its starring contributors. Natera, Inc. (NASDAQ:NTRA) is simply a diagnostics institution specializing successful ctDNA molecular investigating services. On March 03, 2026, Natera, Inc. (NASDAQ:NTRA) banal closed astatine $207.04 per share. One-month instrumentality of Natera, Inc. (NASDAQ:NTRA) was 0.70%, and its shares gained 39.97% implicit the past 52 weeks. Natera, Inc. (NASDAQ:NTRA) has a marketplace capitalization of $28.872 billion.

Carillon Eagle Mid Cap Growth Fund stated the pursuing regarding Natera, Inc. (NASDAQ:NTRA) successful its 4th fourth 2025 capitalist letter:

"Natera, Inc. (NASDAQ:NTRA) is simply a diagnostics institution that provides preconception and prenatal familial investigating services, with its flagship Signatera oncology trial driving growth. In the latest quarter, maturation of Signatera volumes exceeded statement estimates, prompting absorption to rise its gross maturation guidance. Profitability continues to fortify with rising gross margins and sustained affirmative escaped currency flow. With Signatera’s awesome full addressable market, we judge Natera remains good positioned for semipermanent expansion."

Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

Natera, Inc. (NASDAQ:NTRA) is not connected our database of 40 Most Popular Stocks Among Hedge Funds. According to our database, 74 hedge money portfolios held Natera, Inc. (NASDAQ:NTRA) astatine the extremity of the 4th quarter, up from 70 successful the erstwhile quarter. Natera, Inc. (NASDAQ: NTRA) reported gross of astir $666 cardinal successful Q4 2025, representing a maturation of astir 40% compared to Q4 2024. While we admit the imaginable of Natera, Inc. (NASDAQ:NTRA) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article